Kubota Y, Noguchi S, Shuin T, Moriyama M, Hosaka M, Satomi Y, Furuhata A, Kondo I, Sakuramoto T, Yao M
Department of Urology, Yokohama City University, Japan.
Cancer Chemother Pharmacol. 1987;20 Suppl:S56-9. doi: 10.1007/BF00262487.
Further recurrence of superficial bladder cancer after transurethral resection is frequent in patients who have already experienced recurrence. In an attempt to prevent or delay further recurrences in such patients, the effect of preoperative doxorubicin instillation was investigated. A total of 51 patients with recurrent superficial bladder cancer were randomized to receive either TUR alone or TUR with preoperative doxorubicin instillation. Doxorubicin was administered twice a week for 3 weeks before TUR surgery. An objective response (CR + PR) of the tumors was observed at operation in 12 of 25 (48%) evaluable doxorubicin-treated patients. Chemical cystitis was seen in 32% of the patients. Further recurrence after TUR was observed in 13 of 25 (52%) patients in the doxorubicin group, as against 15 of 23 (65%) evaluable patients in the control group. The mean disease-free interval was significantly longer (11.8 as against 7.1 months) in the doxorubicin group. These preliminary results suggest that preoperative doxorubicin instillation might be effective for prolongation of the disease-free interval in patients with recurrent bladder cancer.
对于已经经历过复发的患者，经尿道切除术后浅表性膀胱癌的进一步复发很常见。为了预防或延缓此类患者的进一步复发，研究了术前阿霉素灌注的效果。总共51例复发性浅表性膀胱癌患者被随机分为单纯接受经尿道切除术（TUR）组或术前接受阿霉素灌注的TUR组。在TUR手术前，阿霉素每周给药两次，共3周。在25例可评估的接受阿霉素治疗的患者中，有12例（48%）在手术时观察到肿瘤有客观反应（完全缓解+部分缓解）。32%的患者出现化学性膀胱炎。阿霉素组25例患者中有13例（52%）在TUR后出现进一步复发，而对照组23例可评估患者中有15例（65%）出现复发。阿霉素组的平均无病生存期明显更长（分别为11.8个月和7.1个月）。这些初步结果表明，术前阿霉素灌注可能对延长复发性膀胱癌患者的无病生存期有效。
